Research Topics

Sebastiano Mercadante


Affiliation: La Maddalena Cancer Center
Country: Italy


  1. Mercadante S, Villari P, Ferrera P, Porzio G, Aielli F, Verna L, et al. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. J Pain Symptom Manage. 2006;32:175-9 pubmed
    ..The occurrence of adverse effects for each episode treated was not frequent and intensity was not relevant. IV-MO was effective and safe in most cancer patients receiving TTS-BUP who experienced pain exacerbation. ..
  2. Mercadante S, Ferrera P, Villari P, Casuccio A, Intravaia G, Mangione S. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage. 2009;37:632-41 pubmed publisher
    ..The presence of both poor pain relief and adverse effects is a negative factor for switching prognosis, whereas renal failure is not. ..
  3. Mercadante S, Ferrera P, Villari P. Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients. Support Care Cancer. 2007;15:441-4 pubmed
    ..Further studies should clarify the role and the benefit of TD-BUP in specific clinical circumstances. ..
  4. Mercadante S, Bruera E. Opioid switching in cancer pain: From the beginning to nowadays. Crit Rev Oncol Hematol. 2016;99:241-8 pubmed publisher